{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:05:44Z","timestamp":1778814344992,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["2023KJ032"],"award-info":[{"award-number":["2023KJ032"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2804400"],"award-info":[{"award-number":["2022YFC2804400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2025MS1208"],"award-info":[{"award-number":["ZR2025MS1208"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020QH343"],"award-info":[{"award-number":["ZR2020QH343"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioorg.2026.109520","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:45:52Z","timestamp":1769186752000},"page":"109520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of novel HDAC3 PROTACs for combined therapy with Venetoclax in acute myeloid leukemia"],"prefix":"10.1016","volume":"170","author":[{"given":"Yuxin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingchun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8108-1698","authenticated-orcid":false,"given":"Chong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-4888","authenticated-orcid":false,"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2106","authenticated-orcid":false,"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109520_bb0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.medcli.2018.05.002","article-title":"Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications","volume":"151","author":"Infante","year":"2018","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.bioorg.2026.109520_bb0010","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109520_bb0015","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109520_bb0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109520_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","article-title":"Cell death","volume":"187","author":"Newton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109520_bb0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","article-title":"A guide to cell death pathways","volume":"25","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0045","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109520_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27723","article-title":"A phase 2 trial of CPX-351 combined with venetoclax in relapsed or refractory acute myeloid leukemia","author":"Kadia","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0055","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.109520_bb0060","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.2024026700","article-title":"Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study","volume":"145","author":"Mantzaris","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109520_bb0065","article-title":"A combined histone deacetylases targeting strategy to overcome venetoclax plus azacitidine regimen resistance in acute myeloid leukaemia: three case reports","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0070","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.2024024009","article-title":"How i treat patients with AML using azacitidine and venetoclax","volume":"145","author":"Wei","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109520_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114268","article-title":"A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: clinical safety, efficacy, and correlative analysis","volume":"151","author":"Yang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0080","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109520_bb0085","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0090","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.embor.7400391","article-title":"The histone-binding code of nuclear receptor co-repressors matches the substrate specificity of histone deacetylase 3","volume":"6","author":"Hartman","year":"2005","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bioorg.2026.109520_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: a review","volume":"192","author":"Sarkar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41580-018-0076-0","article-title":"Integrative regulation of physiology by histone deacetylase 3","volume":"20","author":"Emmett","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0105","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13046-020-01792-8","article-title":"Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3-AKT-p21-CDK2 signaling pathway","volume":"39","author":"Wang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109520_bb0110","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1038\/leu.2017.130","article-title":"Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response","volume":"31","author":"Long","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109520_bb0115","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","article-title":"Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARalpha","volume":"30","author":"Dai","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2026.109520_bb0120","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1038\/sj.onc.1207674","article-title":"ETO interacting proteins","volume":"23","author":"Hug","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.109520_bb0125","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41467-024-54860-4","article-title":"CPSF6-RARgamma interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109520_bb0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molcel.2008.02.030","article-title":"Deletion of histone deacetylase 3 reveals critical roles in s phase progression and DNA damage control","volume":"30","author":"Bhaskara","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109520_bb0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","article-title":"Hdac3 is essential for the maintenance of chromatin structure and genome stability","volume":"18","author":"Bhaskara","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.109520_bb0140","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41419-020-02972-2","article-title":"Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.109520_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116663","article-title":"Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with venetoclax against acute myeloid leukemia","volume":"276","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/md22060250","article-title":"Marine cytotoxin santacruzamate a derivatives as potent HDAC1-3 inhibitors and their synergistic anti-leukemia effects with venetoclax","volume":"22","author":"Hao","year":"2024","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bioorg.2026.109520_bb0155","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.0c00442","article-title":"Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acs.jmedchem.1c01472","article-title":"Potent hydrazide-based HDAC inhibitors with a superior pharmacokinetic profile for efficient treatment of acute myeloid leukemia in vivo","volume":"65","author":"Jiang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202500402","article-title":"Proteolysis-targeting chimera (PROTAC): a revolutionary tool for chemical biology research","author":"Pan","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.bioorg.2026.109520_bb0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115693","article-title":"Pharmacological inhibition of HDAC6 suppresses NLRP3 inflammasome-mediated IL-1beta release","volume":"215","author":"Bockstiegel","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113849","article-title":"AZD5438-PROTAC: a selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss","volume":"226","author":"Hati","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0185","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1021\/acs.jmedchem.3c00520","article-title":"Precise conformational control yielding highly potent and exceptionally selective BRD4 degraders with strong antitumor activity","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112800","article-title":"Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)","volume":"208","author":"Cao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0195","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.chembiol.2021.07.002","article-title":"Chemo-proteomics exploration of HDAC degradability by small molecule degraders","volume":"28","author":"Xiong","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0200","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1039\/D0CC03243C","article-title":"Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs","volume":"56","author":"Xiao","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bioorg.2026.109520_bb0205","article-title":"Histone deacetylase 3-directed PROTACs have anti-inflammatory potential by blocking polarization of m0-like into m1-like macrophages","volume":"62","author":"Zhao","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bioorg.2026.109520_bb0210","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.109520_bb0215","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"Gammah2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109520_bb0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2026.109520_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115793","article-title":"Current advances and development strategies of orally bioavailable PROTACs","volume":"261","author":"Zeng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109520_bb0230","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:29:39Z","timestamp":1770175779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"alternative-id":["S0045206826000568"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109520","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of novel HDAC3 PROTACs for combined therapy with Venetoclax in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109520"}}